Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years.

Relapsing-remitting multiple sclerosis alemtuzumab disease progression secondary progressive multiple sclerosis

Journal

Multiple sclerosis journal - experimental, translational and clinical
ISSN: 2055-2173
Titre abrégé: Mult Scler J Exp Transl Clin
Pays: United States
ID NLM: 101668877

Informations de publication

Date de publication:
Historique:
received: 20 04 2020
accepted: 19 10 2020
entrez: 8 1 2021
pubmed: 9 1 2021
medline: 9 1 2021
Statut: epublish

Résumé

Few data exist concerning conversion to secondary progressive MS in patients treated with disease-modifying therapies. Determine the proportion of alemtuzumab-treated patients converting from relapsing-remitting to secondary progressive MS during the CARE-MS core and extension studies. Patients ( Over 6.2 years median follow-up, 20 alemtuzumab-treated patients converted (Kaplan-Meier estimate, 2.7%; 95% confidence interval, 1.8%-4.2%). Sensitivity analysis accounting for dropouts showed similar results (3%), as did analyses using alternative definitions with different EDSS thresholds and/or confirmation periods, and analysis of core study subcutaneous interferon beta-1a-treated patients who received alemtuzumab in the extension. Patients converting to secondary progressive MS were older, and had higher EDSS scores and greater brain lesion volumes at baseline, but did not need additional alemtuzumab or other therapies. The 6-year conversion rate to secondary progressive MS was low for alemtuzumab-treated patients, supporting further study of the role alemtuzumab may play in reducing risk of secondary progression.

Sections du résumé

BACKGROUND BACKGROUND
Few data exist concerning conversion to secondary progressive MS in patients treated with disease-modifying therapies.
OBJECTIVE OBJECTIVE
Determine the proportion of alemtuzumab-treated patients converting from relapsing-remitting to secondary progressive MS during the CARE-MS core and extension studies.
METHODS METHODS
Patients (
RESULTS RESULTS
Over 6.2 years median follow-up, 20 alemtuzumab-treated patients converted (Kaplan-Meier estimate, 2.7%; 95% confidence interval, 1.8%-4.2%). Sensitivity analysis accounting for dropouts showed similar results (3%), as did analyses using alternative definitions with different EDSS thresholds and/or confirmation periods, and analysis of core study subcutaneous interferon beta-1a-treated patients who received alemtuzumab in the extension. Patients converting to secondary progressive MS were older, and had higher EDSS scores and greater brain lesion volumes at baseline, but did not need additional alemtuzumab or other therapies.
CONCLUSIONS CONCLUSIONS
The 6-year conversion rate to secondary progressive MS was low for alemtuzumab-treated patients, supporting further study of the role alemtuzumab may play in reducing risk of secondary progression.

Identifiants

pubmed: 33414927
doi: 10.1177/2055217320972137
pii: 10.1177_2055217320972137
pmc: PMC7750777
doi:

Banques de données

ClinicalTrials.gov
['NCT00548405', 'NCT00530348', 'NCT00930553']

Types de publication

Journal Article

Langues

eng

Pagination

2055217320972137

Informations de copyright

© The Author(s) 2020.

Références

Acta Neurol Scand. 1992 Mar;85(3):212-8
pubmed: 1575007
Neurology. 1996 Jul;47(1):129-39
pubmed: 8710066
Am J Manag Care. 2013 Nov;19(16 Suppl):s294-300
pubmed: 24494618
Neuropsychiatr Dis Treat. 2017 May 18;13:1349-1357
pubmed: 28572730
Lancet Neurol. 2019 Apr;18(4):329-331
pubmed: 30777657
Mult Scler. 2020 Jan;26(1):48-56
pubmed: 30785358
Mult Scler. 2012 Nov;18(11):1625-32
pubmed: 22723573
Lancet. 2012 Nov 24;380(9856):1829-39
pubmed: 23122650
JAMA. 2019 Jan 15;321(2):175-187
pubmed: 30644981
J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):300-6
pubmed: 7897410
Neurology. 2017 Sep 12;89(11):1107-1116
pubmed: 28835401
Arch Neurol. 2005 Sep;62(9):1345-56
pubmed: 16157741
Mult Scler. 2020 Jan;26(1):79-90
pubmed: 31397221
Lancet. 2012 Nov 24;380(9856):1819-28
pubmed: 23122652
AJNR Am J Neuroradiol. 2010 Jun;31(6):983-9
pubmed: 20019103
Mult Scler. 2012 Nov;18(11):1534-40
pubmed: 22917690
J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):208-15
pubmed: 24849515
Ann Neurol. 1999 Sep;46(3):296-304
pubmed: 10482259
Mult Scler. 2019 Oct;25(12):1605-1617
pubmed: 30289355
Neurology. 2006 Sep 26;67(6):944-53
pubmed: 17000959
J Neurol Sci. 2001 Aug 15;189(1-2):13-21
pubmed: 11535229
Mult Scler. 2019 Aug;25(9):1273-1288
pubmed: 30986126
Eur J Neurol. 2015 Jun;22(6):990-1000
pubmed: 25846809
Brain. 2016 Sep;139(Pt 9):2395-405
pubmed: 27401521
J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):67-75
pubmed: 23486991
Mult Scler. 2020 Jul;26(8):955-963
pubmed: 31144568
Neurology. 2017 Sep 12;89(11):1117-1126
pubmed: 28835403

Auteurs

Dana Horáková (D)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

Aaron Boster (A)

The Boster Center for Multiple Sclerosis, Columbus, USA.

Antonio Bertolotto (A)

AOU San Luigi, Orbassano, Torino, Italy.

Mark S Freedman (MS)

University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, Canada.

David H Margolin (DH)

Sanofi, Cambridge, USA.

Tjalf Ziemssen (T)

Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germany Employees of Sanofi during study conduct and analysis.

Classifications MeSH